DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
Most people regain about two-thirds of lost weight within a year of stopping semaglutide or tirzepatide. Here is the trial data, why it happens, and what actually reduces regain.
Across randomized trials, stopping a GLP-1 medication leads to substantial weight regain for most people — typically around two-thirds of the weight lost within a year. The medications manage appetite while taken; they do not permanently reset the body’s weight set-point. This is the single most important thing to understand before starting.
| Drug · trial | After stopping | Net result |
|---|---|---|
| Semaglutide · STEP 1 extension (N=327) | Regained ~11.6 percentage points of lost weight by week 120 (1 year off-drug) — about two-thirds of the loss | Net ~5.6% below baseline retained |
| Tirzepatide · SURMOUNT-4 | Regained ~14% of body weight within 52 weeks of withdrawal (~two-thirds of the loss); 82.5% regained ≥25% by week 88 | Continued treatment instead maintained and added to loss |
Sources: Wilding et al., STEP 1 trial extension, Diabetes Obes Metab 2022 · Aronne et al., SURMOUNT-4, JAMA 2024.
GLP-1 receptor agonists lower appetite and slow gastric emptying while the drug is in your system. They do not cure obesity or permanently change the hormonal set-point the body defends. When the medication clears, ghrelin and other hunger signals return toward baseline, calorie intake rises, and weight follows — the same biology that makes obesity a chronic, relapsing condition. This is why obesity-medicine guidelines increasingly frame GLP-1 therapy as long-term, not a short course.
Planning your costs around long-term use? See our GLP-1 Price Index and per-drug cost breakdowns. Comparing options? All GLP-1s side by side.
In randomized trials, most people regained the majority of lost weight within a year of stopping. In the STEP 1 extension, semaglutide patients regained about two-thirds of their lost weight by week 120. In SURMOUNT-4, tirzepatide patients regained roughly two-thirds (~14% of body weight) within 52 weeks of withdrawal. Continuing the medication maintained the loss.
Regain begins within weeks and continues over about a year. In SURMOUNT-4, 82.5% of people who stopped tirzepatide had regained at least 25% of their lost weight by week 88. The curve is steepest in the first few months as appetite and gastric emptying return to baseline.
GLP-1 medications work by reducing appetite and slowing gastric emptying while you take them. They do not permanently reset the body’s weight set-point. When the drug clears, hunger hormones (ghrelin) and appetite signals return, so calorie intake rises unless other changes hold.
The strongest trial evidence is for continued treatment, often at a maintenance dose — SURMOUNT-4 showed continued tirzepatide maintained and even added to the loss. Where stopping is the goal, clinicians focus on a gradual taper, preserving muscle (resistance training + adequate protein), and sustained lifestyle change. Discuss any taper or stop with your prescriber.
Educational information, not medical advice. Trial figures are population averages; individual results vary. Do not start, change, or stop any prescription medication without your prescriber. Every clinical claim here is verified against the cited peer-reviewed trials and FDA labeling.